Detalhe da pesquisa
1.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
2.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
3.
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
Cancer
; 128(19): 3495-3501, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35942592
4.
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
Cancer
; 128(21): 3880-3887, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107670
5.
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
N Engl J Med
; 380(17): 1628-1637, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018069
6.
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(10): 1385-1415, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022644
7.
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(9): 1108-1135, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181422
8.
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Am J Hematol
; 97(5): E185-E188, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179241
9.
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
J Natl Compr Canc Netw
; 14(12): 1505-1512, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27956535
10.
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
Clin Cancer Res
; 29(12): 2179-2183, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36547666
11.
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
J Clin Oncol
; 40(26): 3032-3036, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820082
12.
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
Blood Adv
; 5(4): 1017-1028, 2021 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33591325
13.
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
Leukemia
; 35(4): 1145-1155, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728186
14.
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
J Clin Oncol
; 39(14): 1584-1594, 2021 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33449813
15.
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).
Leuk Res
; 81: 56-61, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31030089
16.
Project Confirm: Accelerated Drug Approvals for CML-Response.
Clin Cancer Res
; 30(1): 237-238, 2024 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38178776
17.
Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.
Int J Hematol Oncol
; 7(3): IJH04, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30405902
18.
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Leuk Lymphoma
; 64(2): 473-477, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517990
19.
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
Leukemia
; 36(4): 1189-1192, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34975158
20.
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Onco Targets Ther
; 9: 4937-57, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27570458